Conference Coverage

Prediabetes is linked independently to myocardial infarction


 

FROM ENDO 2022

Worsening prediabetes should be addressed

“Prediabetes is not treated with medication, at least initially,” Dr. Thota explained. Rather, patients are educated about important lifestyle changes, such as diet and physical activity, that can reverse the diagnosis. However, patients who remain on a path of worsening hyperglycemia are candidates for more intensive lifestyle intervention and might be considered selectively for metformin.

“Early recognition of prediabetes through screening is important,” Dr. Thota emphasized. The benefit for preventing patients from progressing to diabetes is well recognized, but these data provide the basis for incentivizing lifestyle changes in patients with prediabetes by telling them that it can reduce their risk for MI.

Dr. Deepak L. Bhatt, Brigham and Women’s Hospital Heart & Vascular Center, Boston

Dr. Deepak L. Bhatt

These data have an important message, but they are not surprising, according to Deepak L. Bhatt, MD, executive director, interventional cardiovascular programs, Brigham and Women’s Hospital Heart & Vascular Center, Boston.

“In fact, in daily practice we see a substantial percentage of patients with MI who have prediabetes that had not been previously recognized or formally diagnosed,” Dr. Bhatt said in an interview.

“Identifying these patients – preferably prior to coming in with cardiovascular complications – is important both to reduce cardiovascular risk but also to try and prevent progression at diabetes,” he added.

Dr. Bhatt went on to say that this large analysis, confirming that prediabetes is independently associated with MI, should prompt clinicians to screen patients rigorously for this condition.

“At a minimum, such patients would be candidates for intensive lifestyle modification aimed at weight loss and treatment of frequent coexistent conditions, such as hypertension and dyslipidemia,” Dr. Bhatt said.

Dr. Thota reports no potential conflicts of interest. Dr. Bhatt has financial relationships with more than 30 pharmaceutical companies, many of which make products relevant to the management of diabetes and cardiovascular disease.

Pages

Recommended Reading

Hormones account for 10% of lipid changes after menopause
Federal Practitioner
Updated AHA/ASA guideline changes care for spontaneous intracerebral hemorrhage
Federal Practitioner
Takotsubo syndrome more deadly in men
Federal Practitioner
SGLT2 inhibitors as first-line therapy in type 2 diabetes?
Federal Practitioner
Very high HDL-C: Too much of a good thing?
Federal Practitioner
ADA prioritizes heart failure in patients with diabetes
Federal Practitioner
Antipsychotic tied to dose-related weight gain, higher cholesterol
Federal Practitioner
‘Genetic’ height linked to peripheral neuropathy and certain skin and bone infections
Federal Practitioner
ADA updates on finerenone, SGLT2 inhibitors, and race-based eGFR
Federal Practitioner
SGLT2 inhibitors cut AFib risk in real-word analysis
Federal Practitioner